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Escherichia coliThe metalloprotease PrtV from Vibrio cholerae serves an important function for the bacteria’s ability to
invade the mammalian host cell. The protein belongs to the family of M6 proteases, with a characteristic
zinc ion in the catalytic active site. PrtV constitutes a 918 amino acids (102 kDa) multidomain pre-pro-
protein that so far has only been expressed in V. cholerae. Structural studies require high amounts of sol-
uble protein with high purity. Previous attempts for recombinant expression have been hampered by low
expression and solubility of protein fragments. Here, we describe results from parallel cloning experi-
ments in Escherichia coli where fusion tagged constructs of PrtV fragments were designed, and protein
products tested for expression and solubility. Of more than 100 designed constructs, three produced pro-
tein products that expressed well. These include the N-terminal domain (residues 23–103), the PKD1
domain (residues 755–839), and a 25 kDa fragment (residues 581–839). The soluble fusion proteins were
captured with Ni2+ afﬁnity chromatography, and subsequently cleaved with tobacco etch virus protease.
Puriﬁcation protocols yielded 10–15 mg of pure protein from 1 L of culture. Proper folding of the shorter
domains was conﬁrmed by heteronuclear NMR spectra recorded on 15N-labeled samples. A modiﬁed pro-
tocol for the native puriﬁcation of the secreted 81 kDa pro-protein of PrtV is provided. Proteolytic activity
measurements suggest that the 37 kDa catalytic metalloprotease domain alone is sufﬁcient for activity.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cholera is caused by the motile Gram-negative bacterium Vibrio
cholerae, that spreads via the oral-fecal route and on infection re-
leases several virulence factors [1]. These factors include proteases
that attack the target cells by breaking down tissue barriers and
cellular matrix components, thereby causing necrosis [2–4]. One
of these proteases is the secreted metalloprotease PrtV that exhib-
its a very potent cytotoxic effect. Known substrates for PrtV include
blood plasma clotting components like ﬁbrinogen, ﬁbronectin and
plasminogen, which help in immobilizing foreign entities [5,6].PrtV belongs to the M6 peptidase family, sharing 37% sequence
identity with the immune inhibitor A (InhA)1 from Bacillus thuren-
giensis. The inactive PrtV is natively expressed as a 102 kDa full-
length pre-pro-protein. Besides the signal sequence, PrtV consists
of four domains: the N-terminal domain, the catalytic active M6 do-
main, and the two polycystic kidney disease domains, PKD1 and
PKD2 (Fig. 1).
The N-terminal domain is present in many bacterial proteins,
however, a speciﬁc function for it has not been identiﬁed. The
M6 domain constitutes the catalytic metalloprotease domain with
the characteristic HexxHxxgxxD Zn2+-binding motif [7]. PKD do-
mains are found in a variety of eukaryotic and prokaryotic proteins
consisting of relatively short domains of 80–90 amino acids and
are usually found in the extracellular parts of proteins involved, tobacco
ance.
Fig. 1. Domain organization and maturation products of PrtV. A schematic representation of the four domains in the 102 kDa full-length PrtV.
Table 1
Primers used to amplify sequences of PrtV constructs.
Forward
PrtV f ATGAAAACGATCAAAAAAACGCTATTAGCTGCC
PrtV fN GCTACCATGGCTAAAACGATCAAAAAAACGCTATTAGCTG
PrtV 23f GCTACCATGGCTCAAACACCCATTGATTTAGGCGTGG
PrtV 34f GCTACCATGGAGGATAAATTAATTGAAATGTTAGTCCG
PrtV 84f GCTACCATGGAGCAGCGTGCGAAAATTCTTAAAGTG
PrtV 94f GCTACCATGGATAAGCAAAAAGGCCCGCACAAG
PrtV 108f GCTACCATGGATGTTGGTCAAAAGCGCACGGAC
PrtV 137f GCTACCATGGAGCATACTGAGATGCTCTACGATCG
PrtV 430f GGTACCATGGGCAAACGCGTTGAAGGCATTAAGCCTGCAGAA
PrtV 581f GCTACCATGGCTCAAGGTTTCACCAAAAACGGTGGC
PrtV 591f GCTACCATGGAAGCCAATCACTATTACTTGCTGC
PrtV 607f GCTACCATGGACCAAGGCTTAGCCAATTTGAAACGC
PrtV 748f GCTACCATGGGACGCTTGTCGAAAGTCACCACG
PrtV 755f GCTACCATGGAAAATATCGCGCCTGTGGCT
PrtV 761f GCTACCATGGCTCGCTTTGAACTGAAAGTCG
PrtV 769f GCTACCATGGAGGGGCTCTCTGTGATGTC
PrtV 827f GCTACCATGGATACTCATCAGCAAACCATTAAA
PrtV 838f GCTACCATGGGTCCGAATGCGTTACCACAAGCCAG
Reverse
PrtV 103r GCTTGGTACCTTAACGCGCCTTGTGCGGGCCTTTTTGC
PrtV 115r GCTTGGTACCTTAGTCCGTGCGCTTTTGACCAACATC
PrtV 137r GCTTGGTACCTTACTCTTTCGTCAGGCGGTTATCATC
PrtV 425r GCTTGGTACCTTATTTCACCATGTTCGGGCGTGAGTT
PrtV 434r GCTTGGTACCTTATTCAACCCGTTTCATCGGCAGAG
PrtV 440r GCTTGGTACCTTATTCTGCAGGCTTAATGCCTTCAAC
PrtV 452r GCTTGGTACCTTAATCATCGCCACGGTTCGAGTAGAA
PrtV 573r GCTTGGTACCTTATTCTGCGTTATCGATCAAGGTCTGATTG
PrtV 581r GCTTGGTACCTTAACCTTGGAACGCAAAGCTGGATGTG
PrtV 591r GCTTGGTACCTTATTCGTGGAAGCCACCGTTTTTGG
PrtV 607r GCTTGGTACCTTAGTCAACGTCATTATGGCTGCGC
PrtV 751r GCTTGGTACCTTATTTCGACAAGCGAACAACACCGTAC
PrtV 762r GCTTGGTACCTTAGCGAGCCACAGGCGCGATATTTTCC
PrtV 768r GCTTGGTACCTTACTCGACTTTCAGTTCAAAGCGAGC
PrtV 838r GCTTGGTACCTTAATTCGGTGTGTCCACTTTAATGGTTTGC
PrtV rA GCTTGGTACCTTACAGTTTGACTTTGATGGTGATGGTGGTG
PrtV rev TTACAGTTTGACTTTGATGGTGATGGTGGTG
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N-terminal domain, the function of the PKD domains in PrtV is
not fully understood. It has been suggested that calcium binding
at the PKD1 domain controls domain linker ﬂexibility, and plays
a regulatory role in the auto-proteolytic activity of the 81 kDa
pro-protein [8].
The PrtV protease undergoes several N- and C-terminal modiﬁ-
cations to form a catalytically active protease. The current model
of the maturation process can be described: PrtV is secreted out
of the bacteria as an 81 kDa pro-protein consisting of the M6 do-
main along with PKD1. This form of the protease is known to be
stabilized by calcium ions [6]. Outside the bacterial cell, the
81 kDa form undergoes further cleavage to ﬁnally form the active
M6 metalloprotease believed to comprise the 37 kDa and the
18 kDa domains, which together form the so called 55 kDa active
complex [6].
We perform structural and functional studies of PrtV [5,6,8,9].
For this work, large quantities of pure and soluble protein are
needed. In this study, we address the difﬁculties of protein domain
expression of the PrtV protease by applying a divide and conquer
approach. Screening of domain boundaries for individual domains
and combinations of domains was carried out, and constructs ob-
tained were further screened for solubility and expression levels.
Recombinant PrtV fragments were obtained for three constructs
including the N-terminal domain (residues 23–103), the PKD1 do-
main (residues 755–839), and a longer 25 kDa construct containing
part of the M6 domain and PKD1 (residues 581–839) (Fig. 1). The
previously described puriﬁcation procedure for the 81 kDa
pro-protein [6] was modiﬁed and improved to increase yield and
purity. Interestingly, proteolytic activity measurements of puriﬁed
domains suggest that the 37 kDa domain alone is sufﬁcient for pro-
tein activity.Methods
Construction of expression vectors
The pKVA232 plasmid with a cloned precursor of full-length
PrtV (NP_232622.1) was used as a template for PCR ampliﬁcation
[6]. Various DNA sequences that code for individual or combinato-
rial PrtV domains were ampliﬁed using primers given in Table 1,
which introduced 50Nco1 and 30Acc651 restriction sites for parallel
cloning. The PCR products were cloned in parallel into the multiple
cloning site of a pET24d plasmid coding for His6-tagged protein
and veriﬁed by DNA sequencing. Restriction fragments of con-
structs that expressed (Table 2, constructs marked yellow and
green) were further sub-cloned into pET24d vectors coding for dif-
ferent N terminal His6-carrier protein tags (Table 3) that would
lead to PrtV constructs expressed as fusion proteins. Plasmids
were produced in Escherichia coli DH5 alpha cells and stored
at 80 C.Expression screen of PrtV constructs
A single colony of freshly transformed E. coli Bl21 (DE3) pLysS
strain (Novagen) containing one of the constructed plasmids was
inoculated to 2 ml pre-culture of Luria–Bertani (LB) media contain-
ing 100 lg/ml kanamycin, 50 lg/ml chloramphenicol and 1% glu-
cose, and grown overnight at 37 C with shaking at 200 rpm.
0.5 ml from the pre-cultures were used to inoculate 9.5 ml of
auto-induction LB media containing 100 lg/ml of kanamycin,
1 mM MgSO4, 0.001% glucose, 0.02% lactose, 0.02% glycerol and
20 mM Tris pH 7.4 and grown at 37 C with shaking. After 3 h cells
were cooled to 25 C and grown for 14–16 h with continued shak-
ing. The cells were harvested by centrifugation at 4000g for 20 min
and stored at 80 C. Thawed cells were lysed by sonication and
centrifuged at 18,000g for 30 min. Samples of the supernatant
were analyzed by 15% SDS–PAGE to compare expression and solu-
bility levels.
Table 2
Expression screen. The color code is as follows: red -- represents no expression, yellow -/+ represents low levels of expression, and green ++ represents high levels of expression.
Table 3
Fusion tags used in the expression screen. The cloned and sequenced PCR product was shuttled into ﬁve different pET-system based vectors carrying different N-terminal His6-
tagged fusion partners as listed below. The His6-tagged fusion partners were selected based on their reported properties to improve expression and solubility (for detailed
information see: http://www.embl.de/pepcore/pepcore_services/strains_vectors/vectors/bacterial_expression_vectors).
Vector Tag Description Reference
pETM-11 His6– His6 tag [20]
pETGB1_1a His6–GB1 His6 + protein G binding domain [21]
pETTrxA_1a His6–TrxA His6 + thioredoxin A [22]
pETZZ_1a His6–ZZ His6 + protein A binding domain, double domain [23]
pETMBP_1a His6–MBP His6 + maltose binding protein [24,25]
A. Edwin et al. / Protein Expression and Puriﬁcation 96 (2014) 39–47 41Large scale expression and puriﬁcation of His6–ZZ tagged PrtV 755-
839 (PKD1 domain) and His6-tagged- and His6–TrxA-tagged PrtV
531-839 (25 kDa fragment)
Expression of the His6–ZZ tagged PrtV PKD1domain and His6-
tagged- and His6–TrxA-tagged PrtV 25 kDa fragment was done by
upscaling the above described procedure to 4 L auto-induction
media. All puriﬁcation procedures were done on ice with pre-
cooled solutions. Cell were resuspended in 10 ml per gram wet
weight of lysis buffer consisting of buffer A (20 mM Tris pH 8.0
and 150 mM NaCl) supplemented with 10 mM imidazole, 1 mM
pefabloc (Boehringer), 5 lg/ml lysozyme (Sigma–Aldrich) and
5 lg/ml DNAse 1 (Sigma–Aldrich). Resuspended cells were soni-
cated and insoluble material was separated by centrifugation at40,000g for 40 min at 4 C. The ﬁltered supernatant (0.2 lm syr-
inge ﬁlter, Sarstedt) was applied twice to 4 ml of Ni2+ NTA agarose
(Qiagen) in econo columns (Biorad) that were pre-equilibrated
with 5 column volumes of buffer A supplemented with 10 mM
imidazole and 1 mM pefabloc (Boehringer). The column was
washed with 5 column volumes of buffer A + 1 M NaCl followed
by 5 column volumes of buffer A + 20 mM imidazole. The fusion
protein was eluted with 5 column volumes of buffer A + 300 mM
imidazole.
Tobacco etch virus (TEV) protease cleavage was done by adding
a 1:100 M ratio of enzyme to the eluted fusion protein and allow-
ing the mixture to dialyze against buffer A at 8 C overnight. The
dialyzed sample was passed through 4.5 ml column volume of
Ni2+ NTA agarose (Qiagen) and the ﬂow through containing the
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trated using 3 kDa molecular weight cut off (MWCO) centricon
centrifugal ﬁlters (Millipore) and ﬁltered through a 0.2 lm ﬁlter
(Millipore) prior to loading onto a Superdex 75 16/60 (G.E. Health-
care) size exclusion chromatography column equilibrated with
buffer A. The peak fractions were collected and analyzed by 15%
SDS–PAGE. Both the PrtV 25 kDa fragment and the PrtV PKD1 do-
main protein samples were concentrated to 20 mg/ml. Total yield
resulted in 5 mg and 15 mg from 1 L LB auto-induction media,
respectively. The proteins were ﬂash frozen in 40 ll aliquots in li-
quid nitrogen and stored at 80 C.
The His6-tagged- and His6–TrxA-tagged PrtV 25 kDa fragment
could not be cleaved with TEV protease. Thus the tag remains part
of the puriﬁed protein.Large scale expression and puriﬁcation of His6–TrxA tagged PrtV 23-
103 (N-terminal Domain)
All steps for expression and puriﬁcation of the His6–TrxA
tagged PrtV N domain construct were performed as described
above up to the collection of the ﬂow through from the second
Ni2+ NTA agarose (Qiagen) column. The protein was dialyzed
against buffer B (20 mM Tris pH 7.5 and 100 mM NaCl), ﬁltered
with 0.2 lm (Millipore) and loaded onto a MonoS 5/5 (G.E. Health-
care) column. The column was pre-washed with buffer B and the
protein eluted by a gradient of 0–100% buffer B + 1 M NaCl. The
protein fractions were analyzed by 15% SDS–PAGE and pooled to-
gether. The remaining puriﬁcation protocol followed the same
steps as described above. The PrtV N domain was concentrated
to 20 mg/ml. From 1L media 10 mg of protein was obtained.
The protein was ﬂash frozen in 40 ll aliquots in liquid nitrogen
and stored at 80 C.In vivo expression and puriﬁcation of PrtV 81 kDa pro-proteins
A fresh single colony of V. cholerae KAS202 strain [6] carrying
the pKVA232 plasmid harboring a full length PrtV gene in an arab-
inose inducible system was inoculated to a starter culture of 50 ml
low phosphate medium supplemented with 0.2% w/v casamino
acids (Becton Dickinson and Franklin lakes, USA), 50 lg/ml L-tryp-
tophan (Sigma–Aldrich), 20 mM NaCl, 1 mM MgSO4, 5 mM CaCl2
and 50 lg/ml carbenicillin [6]. Trace elements were also added at
a ﬁnal concentration of 25 lM FeCl3, 10 lM CaCl2, 10 lM ZnSO4,
5 lM MnCl2, 1 lM CuCl2, 1 lM CoCl2, 1 lM NiCl2, 1 lM Na2MoO4,
and 1 lM H3BO3 [10]. The culture was grown overnight at 30 C
with shaking at 200 rpm. The starter culture was used as inoculant
to 10 L of the same media and allowed to grow at 30 C with shak-
ing until the cells reached an OD600 of 0.6 in the mid-exponential
growth phase. Protein expression was induced by adding
0.01% w/v L-arabinose and expressed for 14–16 h with shaking at
30 C. The cells were harvested by centrifugation at 8000g for
40 min. The collected supernatant, including the secreted 81 kDa
pro-protein, was ﬁltered through a 0.2 lm vacuum ﬁlter (Milli-
pore), and loaded onto another 0.2 lm vacuum ﬁlter unit contain-
ing 10 ml DEAE bulk media (G.E. Healthcare) equilibrated with
buffer C (20 mM Tris pH 8.0, 10 mM CaCl2 and 20 mM NaCl). The
media was then washed with 100 ml of buffer C and bound protein
was eluted with 100 ml of buffer C + 500 mM NaCl. The eluted
sample was subjected to sonication on ice and insoluble material
was separated by centrifugation at 40,000g for 1 h. The collected
supernatant was dialyzed against buffer C and loaded to a 5 ml Q
sepharose column (G.E. Healthcare). The bound protein was
washed with buffer C and eluted with buffer C + 500 mM NaCl.Puriﬁcation of the PrtV 37 kDa domain
Puriﬁcation of the 81 kDa pro-protein was performed as de-
scribed above and all buffers used hence forth in the puriﬁcation
of 37 kDa domain contained recommended concentration of the
protease inhibitor cocktail complete-EDTA free (Roche). Puriﬁed
81 kDa PrtV pro-protein was dialyzed with buffer D (20 mM Tris
pH 8.0 and 20 mM NaCl) at 25 C for 16 h. The protein fragments
were loaded onto a 5 ml Q sepharose column (G.E. Healthcare).
The bound protein was washed with buffer D and eluted with buf-
fer D + 500 mM NaCl. The eluted protein was concentrated using
3 kDa MWCO centricon centrifugal ﬁlters (Millipore) and a size
exclusion chromatography was performed using a Superdex 200
16/60 column (G.E. Healthcare) equilibrated with buffer
D + 100 mM NaCl. The fractions containing the 37 kDa domain
were pooled and concentrated to 5 mg/ml. The puriﬁed protein
was ﬂash frozen in 40 ll aliquots in liquid nitrogen and stored at
80 C.Proteolytic activity assay of puriﬁed PrtV fragments
The puriﬁed N-terminal, 81, 37, 25 kDa (His6-tagged), and PKD1
protein fragments were tested for their proteolytic activity. The
calcium was removed from the protein by a quick buffer exchange
over a PD 10 column (G.E. Healthcare) to buffer E (20 mM Tris pH
8.0 and 100 mM NaCl). Commercially available ﬁbrinogen (Sigma–
Aldrich) at a concentration of 1 mg/ml, in buffer F (50 mM HEPES
pH 7.2 and 100 mM NaCl) was used to study the proteolytic activ-
ity of the respective PrtV domains. 100 nM of puriﬁed PrtV do-
mains were added and incubated at 37 C for 16 h. The boiled
samples were subsequently analyzed by 15% SDS–PAGE.Time scale proteolytic activity assay of the 81 kDa pro-protein
Calcium ions were stripped off the puriﬁed 81 kDa pro-protein
by a quick buffer exchange over a PD 10 column (G.E. Healthcare)
to buffer D. Immediately after the buffer exchange, 100 nM of the
calcium-free protein fragment was added to 0.5 mg/ml ﬁbrinogen
in buffer F (time point = 0). The 81 kDa pro-protein was further
incubated at 37 C, and two additional samples of 100 nM each
were taken after 2 and 16 h incubation, respectively, and mixed
with 0.5 mg/ml ﬁbrinogen in buffer F. All three ﬁbrinogen samples
with the added PrtV protease fragments were incubated at 37 C
for 1 h after which the samples were boiled and analyzed by 15%
SDS–PAGE.Isotope labeling and nuclear magnetic resonance (NMR) spectroscopy
Expression of His6–TrxA PrtV N domain and His6–ZZ PrtV PKD1
domain for NMR analysis were done as described earlier using 1 L
of M9 minimal media supplemented with 15NH4Cl as the sole
nitrogen source and trace elements as speciﬁed above. Labeled
PrtV N domain and PrtV PKD1 domain were induced and puriﬁed
as described above for the unlabeled protein. The proteins were ex-
changed into 50 mM potassium phosphate buffer, pH 7.4 and
500 mM NaCl. Unlabeled protein was also expressed using the
same system in M9 minimal medium and puriﬁed as described.
NMR experiments were carried out on a Bruker DRX600 spec-
trometer, equipped with a 5 mm triple-resonance z-gradient
cryo-probe. Fast-HSQC [11]. NMR experiments were recorded at
25 C on 15N-labeled 0.9 mM samples of PrtV fragments in a PBS
buffer (pH 7.4) containing 10% D2O. TOPSPIN, version 2.1 or 3.0
was used for spectrometer control, data processing and analysis
(Bruker Biospin).
Fig. 2. Eluted proteins after nickel afﬁnity chromatography. (A) The PrtV N terminal domain, (B) the PKD1 domain, and (C) the 25 kDa fragment with their fusion proteins
followed by 15% SDS–PAGE. In each lane, 10 ll of the eluted samples were loaded as follows: Lane 1, protein marker; Lane 2, His6-tag; Lane 3, His6-GB1; Lane 4, His6-TrxA;
Lane 5, His6-ZZ; Lane 6, His6-MBP. All constructs show high levels of expression and solubility of the fusion proteins.
Fig. 3. (A) The puriﬁcation proﬁle of the His6-TrxA tagged PrtV N terminal domain followed by 15% SDS–PAGE. Samples were loaded as follows: Lane 1, protein marker; Lane
2, total cell lysate; Lane 3, clariﬁed lysate; Lane 4, elution from the ﬁrst nickel afﬁnity chromatography step; Lane 5, TEV digestion of the eluted protein; Lane 6, separated
protein in the ﬂow through after the second nickel afﬁnity chromatography step; (Lanes 7 and 8 are taken from other gels) Lane 7, elution from the Mono S ion exchange
chromatography; Lane 8, pooled and concentrated protein after size exclusion chromatography. (B) The puriﬁcation proﬁle of the His6-ZZ tagged PrtV PKD1 domain analyzed
with 15% SDS–PAGE. The loading scheme is similar to the ﬁrst six lanes in (A); Lane 7 (from another gel), is the pooled and concentrated protein after size exclusion
chromatography. (C) The puriﬁcation proﬁle of the His6-TrxA-tagged PrtV 25 kDa fragment (total molecular weight equals 39.5 kDa including the 14.5 kDa His6-TrxA tag)
analyzed with 15% SDS–PAGE (Lane 1 is from another part of the gel). The loading scheme is similar to the ﬁrst four lanes in (A).
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Expression, screening and domain identiﬁcation
Various constructs of PrtV were produced corresponding to
the previous reported domain borders and several inter-domain
combinatorial variants (Table 2). Constructs that expressed were
cloned into vectors expressing various carrier proteins as fusions
(Table 3). The vector series was introduced to increase expression
levels, proper folding and solubility of the target protein [12–14].
The fusion tag is linked to the target protein via a TEV protease
recognition site that can be cleaved off with TEV protease during
puriﬁcation in order to produce untagged target proteins. Of
more than 100 constructs, positive hits with high level of expres-
sion included three different constructs: the PrtV N domain (res-
idues 23–103), the PrtV PKD1 domain (residues 755–838) and a
PrtV 25 kDa fragment (residues 581–838 that includes the so
called 18 kDa domain and the PKD1 domain) (Table 2, Fig. 1).
These constructs were selected for further studies. Other con-
structs did not express or were insoluble or lost solubility after
TEV cleavage.
Upscaled expression and puriﬁcation
For upscaling expression and puriﬁcation the His6–TrxA tagged
PrtV N domain, the His6–ZZ tagged PrtV PKD1 domain and the
His6-tagged PrtV 25 kDa fragment fusion proteins were selected.
The selection was based on the expression and solubility patternof the proteins during the initial screen (Fig. 2). Previous studies
suggest that the best choice of constructs for upscaling are the ones
with the smallest fusion tag as this corresponds to the highest per-
centage of the target protein present in the total fusion protein
[13,15]. The His6 and His6–GB1 fusion of PrtV N domain gave high
yields, however a percentage of the expressed protein was also
seen in the insoluble fraction. This was not seen with the His6–
TrxA fusion and consequently it was selected for upscaling
(Fig. 2A). The same expression pattern was observed for the PrtV
PKD1 domain and here the His6–ZZ fusion construct was selected
(Fig. 2B). In the case of the PrtV 25 kDa fragment construct, all fu-
sions yielded similar amounts (Fig. 2C). The three selected protein
fragments were puriﬁed with essentially the same puriﬁcation pro-
tocol based on Ni2+ afﬁnity chromatography, ion exchange chroma-
tography, followed by size exclusion chromatography (Fig. 3A–C).
The fusion partner of the PrtV N domain and the PrtV PKD1 domain
could be removed with TEV protease and the target proteins were
puriﬁed to homogeneity. However, the TEV protease failed to
cleave the 25 kDa fragment, suggesting steric hindrance or a solu-
ble aggregation of the protein [16].
NMR spectra were recorded to validate the structural integrity
of the PrtV N domain and PrtV PKD1 domain. The [1H-15N]-HSQC
spectra recorded at 25 C were excellent where the number of res-
onances corresponds well to the number of residues of the respec-
tive domain (Fig. 4). While the moderate dispersion of resonances
in the N-terminal domain suggests an a-helical protein the well
dispersed resonances of the PKD1 domain is characteristic for a
b-sheet protein.
Fig. 4. [1H-15N]-HSQC NMR spectra of PrtV. The [1H-15N]-HSQC spectra of (A) a
0.9 mM 15N-labeled N-terminal domain of PrtV, and (B) a 0.9 mM 15N-labeled PKD1
domain of PrtV, recorded at 25C.
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The puriﬁcation protocol of the secreted 81 kDa pro-protein
from V. choleraewas modiﬁed to produce higher yields and protein
of higher purity. The addition of the sonication treatment and high
speed centrifugation at 40,000g were key factors contributing for
increased purity. Using the earlier method, which did not include
sonication and used a lower speed centrifugation at 20,000g, a
highly viscous, mucous like phase, developed during theFig. 5. (A) The autoproteolytic activity of the PrtV 81 kDa pro-protein in the absence of ca
marker; Lane 2, 81 kDa PrtV pro-protein; Lane 3, 81 kDa PrtV pro-protein after 5 min; Lan
The puriﬁcation of the PrtV 37 kDa fragment followed by 15% SDS–PAGE. The samples we
81 kDa cleavage fragment loaded onto Q sepharose ion exchange chromatography; Lane
sample loaded on size exclusion chromatography; lane 6, the concentrated elution pea
18 kDa domains were determined by mass spectroscopy [6]. Their positions on the SDSconcentration of the protein. However, this was not seen with
the protein samples puriﬁed with our modiﬁed method. The cen-
trifugation step following the sonication treatment resulted in pel-
let formation which most probably comprised disrupted vesicles,
membrane debris, misfolded and membrane bound proteins [17].
Size exclusion chromatography of the supernatant showed that
the 81 kDa pro-protein puriﬁed in the form of high molecular
weight oligomers (data not shown).
Autoproteolytic activity of the 81 kDa PrtV pro-protein
The autoproteolytic activity of the 81 kDa pro-protein was stud-
ied at various time points at 37 C. The 81 kDa pro-protein is stable
in the presence of calcium, and autoproteolysis can be initiated by
dialysis against calcium free buffers [6]. In agreement with previ-
ous results our study shows that the 81 kDa pro-protein will
immediately be auto-cleaved into two major fragments of 18 and
37 kDa, which after 2 h are suggested to form the so called
55 kDa protein complex ([6], Fig. 5A, Lane 4). However, we now
note that only the 37 kDa fragment appears to be stable during
longer periods of time as the 18 kDa fragment undergoes further
proteolysis and is almost undetectable after 16 h of incubation
(Fig. 5A, Lane 5). The 37 kDa domain is stable and does not undergo
further cleavage and could be puriﬁed with Q sepharose and size
exclusion chromatography (Fig. 5B). Like the 81 kDa pro-protein,
the 37 kDa domain was puriﬁed in a high molecular weight soluble
form.
Proteolytic activity of PrtV fragments
The proteolytic activity of expressed and puriﬁed PrtV frag-
ments was tested using commercially available ﬁbrinogen, a
known substrate of PrtV [6]. The 81 kDa pro-protein is inactive in
the presence of calcium (Fig. 6A). By lowering the calcium concen-
tration the proteolytic activity of the 81 kDa pro-protein was initi-
ated. Interestingly, puriﬁed 37 kDa domains also turned out to be
highly active, whereas, as expected, the PKD1 domain and the
25 kDa fragment did not show any sign of proteolytic activity
(Fig. 6B). We carried out a time course to directly compare the cat-
alytic activity of the 81 kDa pro-protein auto-cleavage products
shown in Fig. 5A without any additional puriﬁcation. In this study,
samples were taken out at the various time points and mixed withlcium followed by 15% SDS–PAGE. The loading scheme is as follows; Lane 1, protein
e 4, 81 kDa PrtV pro-protein after 2 h; Lane 5, 81 kDa PrtV pro-protein after 16 h. (B)
re loaded as follows: Lane 1, protein marker; Lane 2, the 81 kDa pro-protein; Lane 3,
4, elution from the Q sepharose ion exchange chromatography; Lane 5, the protein
k from size exclusion chromatography. The molecular weights of the 37 kDa and
–PAGE are indicated.
Fig. 6. Proteolytic activity of PrtV domains using ﬁbrinogen as substrate. (A) Lane 1, protein marker; Lane 2, ﬁbrinogen + 100 nM 81 kDa PrtV pro-protein + 10 mM CaCl2. (B)
The activity of PrtV fragments on ﬁbrinogen followed by 15% SDS–PAGE. 10 lg of sample was loaded in each well as follows: Lane 1, protein marker; Lane 2, ﬁbrinogen
control; Lane 3, ﬁbrinogen + 100 nM 81 kDa PrtV pro-protein; Lane 4, ﬁbrinogen + 100 nM 37 kDa PrtV domain; Lane 5, ﬁbrinogen + 100 nM 25 kDa PrtV protein; Lane 6,
ﬁbrinogen + 100 nM PrtV PKD1 domain. (C) 100 nM of the sample was added to 1 mg/ml ﬁbrinogen, incubated at 30 C for 1 h, and loaded on the gel as follows: Lane 1,
protein marker; Lane 2, ﬁbrinogen + 81 kDa pro-protein immediately after removal of calcium; Lane 3, ﬁbrinogen + 81 kDa pro-protein incubated 2 h at 37 C after removal of
calcium; Lane 4, ﬁbrinogen + 81 kDa pro-protein incubated for 16 h at 37 C after removal of calcium.
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16 h comprised predominantly the 37 kDa domain (Fig. 5A, Lane
5) and that this domain was equally, or perhaps even more, active
in comparison with the activity of the fragments present after only
2 h of incubation (Fig. 5A, Lane 4 and 5; Fig. 6C, Lanes 3 and 4).
Discussion
The secreted metalloprotease PrtV is a potent virulence agent in
the arsenal of V. cholerae causing instant cytotoxic effects during
infection [6]. Several steps occur during the maturation process
of the full length 102 kDa pre-pro-protein, undergoing the ﬁrst
cleavage steps in the bacterial cell before secretion as an 81 kDa
intermediate pro-protein. By the removal of calcium this inactive
pro-protein is auto-cleaved into smaller domains/fragments until
it reaches its mature state as an active metalloprotease [6]. So far
structural studies of natively produced and puriﬁed 81 kDa pro-
protein have not been successful. We therefore set out to identify
and purify individual domains of the protein, which requires that
constructs of individual domains can be successfully created.
Approximate domain borders determined by mass spectroscopy
have been reported [6], however, optimized constructs that yield
soluble proteins were not available.
In order to identify, overexpress and purify domains of PrtV, we
employed several strategies that followed a divide and conquer ap-
proach. Our ‘‘domain phasing’’ and expression screening resulted
in three target constructs: the PrtV N domain (residues 23–103),
the PrtV PKD1 domain (residues 755–838) and the PrtV 25 kDa
fragment (residues 581–838, which includes the so called 18 kDa
fragment and the PKD1 domain). Interestingly, only slight differ-
ences in construct length resulted in these highly expressed and
soluble constructs (Table 2). The PrtV N and PKD1 domains ex-
pressed well and could be puriﬁed as monomers in soluble form
at high concentrations: 20 mg of pure protein was obtained from
1 L media. The PrtV 25 kDa fragment could not be cleaved with TEV
protease and could only be puriﬁed as high-molecular weight sol-
uble aggregate.
In parallel with the expression screens we also optimized the
puriﬁcation protocol of the 81 kDa pro-protein secreted from its
native source, i.e. the V. cholerae bacterium. Our aim here was to
produce protein more suitable for crystallization purposes. How-
ever despite many attempts, crystals have so far not been obtained.
The addition of the sonication treatment and high speed centrifu-
gation at 40,000g to the previous puriﬁcation protocol [6] removeda highly viscous, mucous like phase that otherwise developed dur-
ing concentration of the protein. The centrifugation step after the
sonication treatment resulted in pellet formation, which most
probably included disrupted vesicles, membrane debris, mis-
folded and membrane bound proteins [17]. These impurities,
now removed, are not visible on standard SDS–PAGE.
The autoproteolytic activity of the puriﬁed 81 kDa pro-protein
was investigated. In the presence of calcium, the 81 kDa pro-pro-
tein is inactive, however, removal of calcium immediately starts
an auto-proteolytic process and after 2 h at 37 C, the 81 kDa
pro-protein is degraded into the 37 and 18 kDa domains, i.e. the
so called 55 kDa complex, in agreement with earlier reported ﬁnd-
ings [6] (Fig. 5A, Lanes 3 and 4). Interestingly, we found that with
time the 18 kDa domain also will degrade leaving only the 37 kDa
domain in solution (Fig. 5A, Lane 5). The 37 kDa domain (residues
106–434) is stable and could be puriﬁed with a combination of an-
ion exchange and size exclusion chromatography (Fig. 5B).
We next asked if the 18 kDa domain is really necessary for
protease activity. Therefore, the proteolytic activity of the 81 kDa
pro-protein, as well as puriﬁed PrtV domains, was assayed using
commercially available ﬁbrinogen, a known substrate of PrtV [6].
The degradation of ﬁbrinogen was monitored after 16 h of incuba-
tion of PrtV protein samples at 37 C in a calcium-free solution
(Fig. 6B). The results showed that puriﬁed 37 kDa domains had
proteolytic activity towards the ﬁbrinogen substrate. This suggests
that the 18 kDa domain is not necessary for protease activity
(Fig. 8). We also evaluated the proteolytic activity of the 37 kDa
domain before puriﬁcation (Fig. 6C). Noteworthy, the cleavage pat-
tern of the ﬁbrinogen substrate obtained by the 16 h auto-cleaved
81 kDa pro-protein and the puriﬁed 37 kDa domain are different
from each other (compare Fig. 6B Lane 4 with Fig. 6C Lane 4). Even
after incubation at 48 h the cleavage pattern of ﬁbrinogen shown
in Fig. 6B, lanes 3 and 4, does not change and ﬁbrinogen is not
cleaved further (data not shown). We cannot explain this differ-
ence. One could speculate that non-puriﬁed 37 kDa domains are
associated with small molecular weight molecules/cleavage frag-
ments that affect the activity of the protein and that these mole-
cules are removed during puriﬁcation. Size exclusion
chromatography of puriﬁed 37 kDa domains shows that the pro-
tein is of high molecular weight. Thus observing catalytic activity
suggests that this is not a case of soluble aggregation, rather that
the fragments form high molecular weight multimers.
Based on auto-proteolysis and activity assays we propose a new
model for PrtV maturation (Fig. 7). The 37 kDa active domain
Fig. 7. Calcium-dependent auto-proteolytic cleavage of the 81 kDa pro-protein results in formation of the 37 kDa active domain. The lightning bolt symbolizes the calcium-
dependent cleavage between residues Leu749 and Ser750 [6].
Fig. 8. Sequence alignment (Blast, [26] of the 37 kDa fragment of PrtV from V. cholerae and the human ADAM-8 domain. The sequence identity is 28% for 67 amino acids.
Secondary structural elements from the ADAM-8 structure (pdb code 4dd8 [18]) are shown as red bars. The secondary structure elements predicted for PrtV with jpred3 [27]
are shown in blue (E, b-strands) and red (H, a-helices). The conserved HexxHxxgxxD motif is highlighted in yellow. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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protease domain with the characteristic HexxHxxgxxD Zn2+-bind-
ing motif [6,8]. A search at the protein data bank shows only 2
structures with low level of sequence identity to the 37 kDa do-
main. These include the human ADAM-8 metalloproteinase (pdb
code 4dd8, [18]) and the zinc endoprotease from Streptomyces
caespitosus (pdb code 1c7k, [7]). For the latter structure only 15
residues comprising the Zn2+-binding motif are conserved. Se-
quence alignment with the ADAM-8 protein resulted in 28% iden-
tity over 67 aligned residues over the active site. It is therefore
plausible that PrtV has a structure similar to ADAM-8 for residues
Asp315–Asn386 (Fig. 8).
The N-terminal and PKD1 domains were expressed and puriﬁed
to homogeneity. However, from the four constructs made of the
PKD1 domain, only one including residues 755–838 could be ex-
pressed at high concentrations (Table 2). We have solved the crys-
tal structure of the PKD1 domain at 1.1 Å resolution [8]. Thedomain forms a b-sandwich fold typical for PKD domains. A cal-
cium binding site was identiﬁed in the PKD1 domain positioned
close to its N-terminus. It was suggested that this calcium-binding
site plays an important role in the regulation of the calcium-depen-
dent auto-proteolysis mechanism [8]. Analysis of the domain
boundaries as observed from the crystal structure of the PKD1 do-
main showed that any construct shorter than 757–838 would cut
the ﬁrst b-strands comprising the scaffold of the domain [8]. This
would explain the lower protein expression levels and reduced
protein stability of the constructs in the vicinity of this domain
border (Table 2). The results support our approach to construct
multiple variants of the same domain. Our strategy here also cor-
relates with similar approaches from other labs that had con-
structed different domain lengths in order to achieve expression
and solubility [13,14,19]. The same is true for the PrtV 25 kDa frag-
ment where only one construct including residues 581–838 could
be expressed (Table 2). This approach was however not fruitful in
A. Edwin et al. / Protein Expression and Puriﬁcation 96 (2014) 39–47 47the case of the 37 kDa domain from the M6 domain, which con-
tains the catalytic active site. Still we have not been able to pro-
duce any 37 kDa domain recombinantly. Although E. coli is a
Gram negative bacterium like V. cholerae, it may lack several key
factors like chaperons that are necessary for protein folding and
stability, and natively present in V. cholerae, a possibility that we
will address in future experiments.Acknowledgments
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